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Abstract
Objective: To perform an update on cannabis abuse by patients with 
psychiatric disorders. Method: A search was performed in the electronic 
databases Medline, The Cochrane Library Database, Lilacs, PubMed, and 
SciELO, using the keywords ‘marijuana abuse’, ‘cannabis abuse’, ‘psychiatric 
disorders’, and ‘mental disorders’. Articles published until December 2009, 
dealing with cannabis abuse and dependence in association with other 
psychiatric disorders were included. Results: Cannabis abuse was found 
to be associated with increased risk for the onset of schizophrenia and 
chronic psychotic symptoms, although these findings require confirmation 
from additional research. Cannabis seems to be one of the drugs of choice 
of individuals with bipolar disorder, despite evidence that manic states can 
be induced by its use. Cannabis abuse also occurs frequently in individuals 
with anxiety disorders, but the relationship between the chronic nature of 
these conditions and the use of marijuana remains uncertain. In respect 
to depression, there is no clear evidence to date that depressive patients 
use cannabis as a form of self-medication. In individuals with psychiatric 
disorders, the use of cannabis has been associated with increased positive 
symptoms, additional negative symptoms in the course of illness, impaired 
treatment compliance, and more hospitalizations. Conclusion: The abuse 
of cannabis by patients with psychiatric disorders such as schizophrenia and 
mood and anxious disorders has a negative impact both in the acute and 
advanced stages of these conditions, although further investigation on this 
association is still necessary.
Descriptors: Cannabis; Marijuana abuse; Dependency (psychology); Mental 
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Resumo
Objetivo: Realizar uma atualização sobre o abuso de cannabis em 
pacientes com transtornos psiquiátricos. Método: Busca de artigos nas 
bases de dados eletrônicas Medline, The Cochrane Library Database, 
Lilacs, PubMed e SciELO, utilizando os descritores “marijuana abuse” 
”cannabis abuse”, “psychiatric disorders” AND “mental disorders”; incluindo 
artigos que avaliaram ambas as exposições para abuso e dependência de 
cannabis e qualquer outro transtorno psiquiátrico. Foi considerado o 
período até dezembro de 2009. Resultados: Observou-se que o abuso 
frequente de cannabis pode aumentar o risco para o desenvolvimento de 
esquizofrenia e de sintomas psicóticos crônicos, embora estes achados 
ainda careçam de comprovação. A cannabis parece ser uma das drogas 
de escolha de portadores de transtorno afetivo bipolar, sendo que é 
descrito que estados maníacos podem ser induzidos pelo seu consumo. 
O abuso de maconha também frequentemente co-ocorre em indivíduos 
com transtornos ansiosos, sendo que a relação de cronicidade destas 
condições e o consumo de maconha ainda é incerta. Para depressão ainda 
não existem evidências claras que apontem que o consumo de cannabis 
ocorre como forma de automedicação. Em indivíduos com transtornos 
psiquiátricos, há relatos de que o uso da cannabis pode exacerbar sintomas 
positivos, somar efeitos negativos no curso do transtorno, contribuir para 
pior adesão ao tratamento e levar a maior número de hospitalizações. 
Conclusão: O abuso de cannabis em pacientes com transtornos 
psiquiátricos como esquizofrenia, transtornos do humor e ansiosos tem 
impacto negativo tanto na fase aguda quanto em fases mais avançadas 
destas condições, embora futuros estudos avaliando estas associações 
ainda sejam necessários.
Descritores: Cannabis; Abuso de maconha; Dependência (psicologia); 
Transtornos mentais
Introduction
After the identification of ∆9-tetrahydrocannabinol (∆9-THC) 
in the 1960s, the cloning of the CB
1
 cannabinoid receptor, and 
the ensuing discovery of the endocannabinoid system in the 1990s, 
a growing volume of studies have focused on the involvement of 
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Recent reviews reproduce the association between the use of 
cannabis and the onset of acute psychotic states reported in the 
1930s.14-16 The same reviews also indicate that the frequent abuse 
of cannabis can increase the risk to develop schizophrenia and 
chronic psychotic symptoms.2,7,15 This risk has been reported as 
ranging between 1.2 and 2.8 (95% CI, Odds Ratio), particularly 
in more vulnerable individuals, with cannabis appearing as a risk 
factor for the development of chronic psychoses. These are the 
results of longitudinal studies that controlled for other risk factors 
and that investigated temporality, causality, association strength, 
biological vulnerability, and dose-effect relationships (dose, onset, 
and duration of exposure).2,7 Cannabis abuse can, therefore, be 
considered as one of the elements in a causal constellation that 
leads to schizophrenia in adulthood.7
In schizophrenia patients, the use of cannabis can exacerbate 
psychotic symptoms (especially positive), induce relapse, worsen 
negative symptoms in the course of illness, and contribute to 
poor treatment compliance, leading to more hospitalizations.9,14,15
Impaired academic outcome (low educational and learning 
performance), professional skills, social functioning, and 
neurocognition (motivation, planning, visuospatial functions, 
impulsivity, attention, and hyperactivity) have been observed in 
individuals with psychotic disorders as well as in regular users of 
the drug.2
Such impairments become less likely to respond to treatment 
in function of the precociousness of the exposure to marijuana 
abuse, particularly during the phase of brain development.17 
This can be explained by the fact that around 16 years of age the 
endocannabinoid system reaches its peak in terms of receptor 
density;18,19 hence the hypothesis that a chronic alteration in this 
system (i.e. decrease in the density of CB
1
 receptors) might cause 
permanent neuropsychological and neurocognitive deficits.2
A possible neurobiological mechanism to explain cannabis -
related deficits in schizophrenia patients involves the changes in 
the signaling and functioning of endogenous cannabinoids such 
as anandamide and its analogues. Another possible explanation is 
related to the facilitation of the mesolymbic dopaminergic system 
and to the involvement of other GABAergic and glutamatergic 
neurotransmitters.14 Although many models have been proposed 
to explain the etiological relationship between cannabis abuse 
and psychosis, no hypothesis was able to adequately elucidate all 
the associations thus far. Thus, researchers have advocated for the 
integration of the cannabinoid system into the current etiological 
hypotheses of schizophrenia.2,20
2. Anxiety disorders
Anxiety symptoms have been regarded as one of the most 
frequently reported adverse reactions related to the use of 
marijuana.21,22 These symptoms are more common among 
inexperienced users and people who suddenly stop use after a 
period of heavy daily abuse (at least six cigarettes/day).22
Acute intoxication can cause anxiety symptoms due to the 
impairment in cognitive functioning and to alterations in 
perception. Similarly, cannabis abstinence can cause anxiety 
this system in psychiatric disorders such as schizophrenia, bipolar 
affective disorder (BAD), major depression, and anxiety.1-4
A number of epidemiological studies indicate that people with 
severe mental disorders are more likely to use, abuse, and depend 
on psychoactive substances – especially cannabis – as compared to 
the general population.4-6 The rates of cannabis abuse have been 
reported to be 10.1% higher in schizophrenia, 14.5% among 
patients in a manic episode, 4.1% in major depression, 4.3% in 
panic disorder, and 2.4% in patients with phobias.1,2,4
The association between cannabis abuse (age at onset and 
quantity and duration of exposure) in patients with psychiatric 
disorders has been recognized as an independent risk factor for 
the occurrence of acute psychotic episodes, cognitive impairment, 
behavioral disturbances, symptom exacerbation, and negative 
events in the course of illness.7-9 These findings are a source of 
new lines of investigation and should be taken into account in the 
organization of services for patients with comorbid diagnoses.10,11 
In spite of the changes occurring in mental health services,12 
the treatment proposals for patients with comorbid psychiatric 
disorders remain inconsistent and are frequently incompatible 
with some psychopharmacological interventions. Similarly, 
treatment strategies directed to specific subgroups in different 
assistance settings are deficient. For example, only 12% of patients 
with cannabis-related problems and other comorbidities receive 
treatment for both conditions in the United States of America 
(USA).11 Empirical populational data from developing countries 
in this regard are scarce.4
Based on these considerations, this study was aimed at 
performing an update on cannabis abuse and dependence in 
patients with psychiatric disorders.
Method
The search for articles was performed in the electronic databases 
Medline, The Cochrane Library Database, Lilacs, PubMed, and 
SciELO, using the keywords ‘marijuana abuse’, ‘cannabis abuse’, 
psychiatric disorders’, and ‘mental disorders’.
The articles included investigated cannabis (marijuana) abuse 
and dependence associated with psychiatric disorders and were 
published until December 2009. There were no restraints in 
respect to the language of publication. The reference lists of the 
selected articles were checked in order to identify works that were 
not detected in the initial search.
Results
1. Schizophrenia and psychoses
Epidemiological studies demonstrate a high prevalence of 
cannabis abuse in individuals with psychoses,13-15 with rates of 
23% for current use, 42.1% for lifetime use, and 22.5% for abuse.1
One possible explanation, based mostly on self-report 
evaluations, associates these high rates of cannabis use with 
self-medication attempts, according to the “dysphoria relief ” 
model and unpleasant states in schizophrenia. Nonetheless, 
the epidemiological evidence available lends no support to this 
hypothesis.
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symptoms including panic attacks, generally occurring between 
the 2nd and 6th days after withdrawal and lasting from 4 to 
14 days.23
The use of cannabis seems to contribute to the early appearance 
of panic attacks in vulnerable individuals. This is especially likely 
to happen among teenagers, in whom the continuous use may 
provoke anxiety symptoms regardless of genetic, individual or 
environmental characteristics.1,2,23
The relationship between marijuana and anxiety disorders seems 
to be modulated by the interaction of ∆9-THC with GABA, 
glutamate, serotonin, and noradrenalin pathways.2,23 Evidence 
points out to the existence of an association between previously 
existing anxiety disorders and the use of cannabis. This situation 
contributes for the establishment of a cycle of “self-medication” 
and eventual worsening of pre-existing anxiety symptoms. 
Individuals with anxiety disorders are at a greater risk of using 
cannabis in an attempt to feel relaxed and to reduce anxiety. 
Paradoxically, the progressive and exaggerated use contributes to 
increase anxiety symptoms, possibly due to factors related to the 
dose of ∆9-THC. At last, anxiety symptoms might be predictors of 
increased cannabis use and of the development of dependence.1,23
Despite the growing understanding on the topic, doubts persist 
in relation to the chronicity of anxiety symptoms associated with 
the use of cannabis, since there is a lack of longitudinal studies 
evaluating clinical outcomes in patients with anxiety disorders 
using the drug.2,23 Apparently, in individuals with a genetic 
predisposition for the development of anxiety disorders, cannabis 
can cause alterations in the endocannabinoid system that would 
result in persistent anxiety symptoms.23
The mechanisms through which marijuana interferes with 
anxiety are complex and have not been fully understood to date. 
Such mechanisms include, among others, interactions between ∆9-
THC and non-cannabinoid neurotransmitters; a dose-dependent 
relationship with ∆9-THC; and the concentrations of other 
cannabinoids such as cannabidiol, which has anxiolytic effects.2,23
3. Mood disorders
Cannabis seems to be one of the main drugs of abuse in patients 
with BAD. Compared to the general population, patients with 
BAD are twice as likely to use marijuana in life (34% vs. 64%) 
and to develop manic symptoms.2
Three theories have been proposed to explain the use of 
marijuana by BAD patients.2 The first hypothesis refers to a 
possible hypersensitivity to illicit substances in this population: 
genetically predisposed individuals would be more vulnerable to 
environmental, psychological, and biological risks, so that even 
the consumption of small quantities of these substances could 
be more harmful to this population. The second theory is that 
of “self-medication”, similar to the “theory of dysphoria relief ” 
in schizophrenia. The use of marijuana would relieve dysphoric 
symptoms, subsequently evolving to cannabis dependence with 
a consequent worsening of the initial dysphoria. The third 
hypothesis is the “multiple factor” theory, according to which low 
academic performance, limited economical resources, impaired 
interpersonal and social skills, social isolation, and acceptance by 
groups in which the use of marijuana is facilitated could be related 
to the emergence of the disorder.1,2,24 
Thus far, few systematic investigations have been performed 
on the physiopathological involvement of cannabis with the 
endocannabinoid system in BAD. Some of these studies state that 
the manic symptom at the onset of BAD is unable to predict the 
future use of cannabis by this population.2 Based on correlational 
studies, some authors have proposed the use of cannabis derivatives 
such as cannabidiol for the relief of manic and depressive 
symptoms;2 however, initial evidence from animal and human 
research does not support the usefulness of this cannabinoid in 
these cases.25,26
Scientific evidence on the association between depressive states 
and cannabis abuse is scarcer.2 There seems to be no increased risk 
for depression associated with the occasional use of marijuana,4,27 
but the heavy and regular use of the drug co-occurs with depression 
in a greater frequency than at random. Similarly to what happens 
in other psychiatric conditions described here, some studies suggest 
that the use of marijuana among patients with depressive disorders 
may be a form of “self-medication”, although this notion is not 
supported by currently available evidence.4,28
There is no evidence on the involvement of specific 
neurotransmitter systems in the facilitation of depressive disorders. 
The effects of the abuse of cannabis related to increased risk for 
depression are probably mediated more by social aspects than by 
characteristic physiopathological mechanisms, since the regular 
and early abuse of this substance might be associated with various 
environmental situations such as unemployment, criminality, 
and educational impairment.1,4 Additionally, the comorbidity 
between depression and cannabis use may be underdiagnosed, 
since cannabis dependence can mimic depressive symptoms in 
some individuals.4
Discussion
In general, studies on the association between cannabis use and 
mental disorders performed in the 1980s and 1990s were mostly 
uncertain in regard to the association of this substance with 
chronic psychoses (especially schizophrenia), whereas more recent 
evidence speaks in favor of this association,2,4,29 although not in 
a conclusive manner. In respect to mood and anxiety disorders, 
the contrasting findings led to even greater uncertainty, impeding 
generalizations.2,23
The evidence available to date provides arguments both for 
cannabis prevention and legalization policies. Younger individuals 
that use cannabis are more vulnerable to the development of 
psychiatric disorders, with an increased risk for suffering the 
adverse consequences of the early exposure to the substance in 
comparison to adult users, and this may have a negative impact 
on their academic life and global functioning. Legalization would 
lead to an increased offer of the drug, exposing more people to the 
use of marijuana and, therefore, to its associated complications, 
among which are the development and worsening of psychotic 
disorders.30-32
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People with psychiatric comorbidities constitute a group that 
poses great treatment challenges.11 Ideally, the most effective 
models of treatment services should integrate the traditional 
psychiatric therapy for psychoses and for substance abuse, 
associating supervised psychopharmacotherapy, psychoeducation, 
cognitive-behavioral therapy, family and motivational therapy, 
social skills training, and group therapy with samples that are 
homogeneous in respect to diagnosis. In addition, the availability 
of therapeutic homes for unsuccessful outpatient cases is 
desirable.4,10,11
 The development of standardized guidelines for the 
identification of cannabis abuse in psychiatric populations aimed 
at reducing the rates of non-detection are among the major 
recommendations for the clinical practice.4,11
Despite the controversies in research findings, it can be stated 
that researchers are only beginning to understand how marijuana 
can have detrimental effects in the course of the illness of some 
patients with psychiatric disorders, both in the acute and chronic 
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Conclusion
The abuse of cannabis by patients with psychiatric disorders 
such as schizophrenia and mood and anxiety disorders seems to 
have a negative impact both in the acute and advanced stages 
of these conditions.2,4,35 Prevention strategies in primary care, 
integrated treatment efforts, and the performance of longitudinal 
studies should be encouraged in order to gather more evidence 
and improve prognosis in the short-term.
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